fosbretabulin and rhein

Visualization of tumor necrosis can determine tumor response to therapy. Our previous study showed that the rhein-based magnetic resonance imaging (MRI) contrast agent with alkane linker (GdL. Three rhein-based MRI agents were synthesized with a tetracarbon ether (GdP1), a hexacarbon ether (GdP2), and a lysine (GdP3) linker, respectively. Their octanol-water partition coefficients (log P) and cytotoxicity were determined. Necrosis avidity of the leading agent was explored on HepG2 cells and ischemia reperfusion-induced liver necrosis (IRLN) rats by MRI. The effect of visualization of tumor necrosis was tested on nude mice with W256 tumor treated by combretastatin-A4 phosphate (CA4P). DNA binding assays were applied to evaluate the possible necrosis-avidity mechanism of the leading agent.. The log P of three agents (- 1.66 ± 0.09, - 1.74 ± 0.01, - 1.95 ± 0.01) decreased when compared with GdL. GdP1 may serve as a potential candidate for early evaluation of tumor response to CA4P treatment.

Topics: Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Drug Design; Humans; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Necrosis; Rats; Rats, Sprague-Dawley; Stilbenes; Tissue Distribution

This study aimed to synthesize a necrosis-avid agent using rhein as a precursor and labeled with gallium-68 (Ga-68) for positron emission tomography/computed tomography (PET/CT) imaging, to evaluate response to anticancer treatment in a mouse model.

Topics: Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; Cattle; Cell Line, Tumor; DNA; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Male; Mice; Necrosis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sarcoma 180; Stilbenes; Tissue Distribution; Treatment Outcome